Clinical Outcomes Associated with Polymyxin B Dose in Patients with Bloodstream Infections Due to Carbapenem-Resistant Gram-Negative Rods

There is significant variation in the use of polymyxin B (PMB), and optimal dosing has not been defined. The purpose of this retrospective study was to evaluate the relationship between PMB dose and clinical outcomes. We included patients with bloodstream infections (BSIs) due to carbapenem-resistan...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Nelson, Brian C., Eiras, Daniel P., Gomez-Simmonds, Angela, Loo, Angela S., Satlin, Michael J., Jenkins, Stephen G., Whittier, Susan, Calfee, David P., Furuya, E. Yoko, Kubin, Christine J.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2015
Sujets:
Clinical Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4604419/
https://ncbi.nlm.nih.gov/pubmed/26324272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00844-15
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires